




# PHARMACEUTICAL 2017

Neos Therapeutics Inc.  
Rank 239 of 292





# PHARMACEUTICAL 2017

Neos Therapeutics Inc.  
Rank 239 of 292

The relative strengths and weaknesses of Neos Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Neos Therapeutics Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Neos Therapeutics Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 116% points.

The company's Economic Capital Ratio, given in the ranking table, is -106%, being 109% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	55,269
Cost of Goods Sold	11,437
Intangible Assets	0
Liabilities, Current	21,645
Liabilities, Non-Current	60,045
Other Assets	17,797
Other Compr. Net Income	-1.0
Other Expenses	49,309
Other Liabilities	0
Other Net Income	-6,909
Other Revenues	9,154
Property and Equipment	7,076
Research and Development	12,207
Selling, General and Administrative Expense	12,625

Output Variable	Value in 1000 USD
Assets	80,142
Liabilities	81,690
Expenses	85,578
Revenues	9,154
Stockholders Equity	-1,548
Net Income	-83,333
Comprehensive Net Income	-83,334
Economic Capital Ratio	-106%